Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Wednesday

Sagimet Biosciences (NASDAQ:SGMT) is expected to post its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 9:30 AM ET.

Sagimet Biosciences Price Performance

SGMT opened at $5.41 on Monday. The company has a market capitalization of $175.93 million, a price-to-earnings ratio of -3.04 and a beta of 3.35. Sagimet Biosciences has a 1-year low of $1.73 and a 1-year high of $11.41. The business has a 50 day moving average price of $5.78 and a two-hundred day moving average price of $6.68.

Insider Activity

In other news, CEO David Happel sold 12,101 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total transaction of $64,861.36. Following the completion of the sale, the chief executive officer owned 677,621 shares in the company, valued at approximately $3,632,048.56. This represents a 1.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 14.70% of the company’s stock.

Institutional Investors Weigh In On Sagimet Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada lifted its holdings in shares of Sagimet Biosciences by 819.2% during the fourth quarter. Royal Bank of Canada now owns 4,927 shares of the company’s stock valued at $29,000 after purchasing an additional 4,391 shares during the last quarter. Bank of America Corp DE increased its stake in Sagimet Biosciences by 81.8% in the 2nd quarter. Bank of America Corp DE now owns 9,943 shares of the company’s stock worth $76,000 after purchasing an additional 4,473 shares in the last quarter. Virtu Financial LLC purchased a new position in Sagimet Biosciences in the 4th quarter worth about $62,000. Jefferies Financial Group Inc. acquired a new stake in Sagimet Biosciences during the 3rd quarter worth about $95,000. Finally, LPL Financial LLC raised its holdings in Sagimet Biosciences by 31.3% during the 4th quarter. LPL Financial LLC now owns 20,574 shares of the company’s stock worth $122,000 after buying an additional 4,899 shares during the period. 87.86% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SGMT shares. Citigroup reissued an “outperform” rating on shares of Sagimet Biosciences in a research note on Friday, November 14th. Guggenheim assumed coverage on Sagimet Biosciences in a research note on Tuesday, February 3rd. They set a “buy” rating and a $27.00 target price for the company. Wall Street Zen lowered Sagimet Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Zacks Research cut shares of Sagimet Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Finally, Citizens Jmp upped their price target on shares of Sagimet Biosciences from $33.00 to $35.00 and gave the company a “market outperform” rating in a report on Friday, November 14th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.00.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.